Ecabet

• CAT Number: M014407
• CAS Number: 33159-27-2
• Molecular Formula: C20H28O5S
• Molecular Weight: 380.5
• Purity: ≥95%
• Storage: RT
• IUPAC Name: (1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-6-sulfo-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylic acid
• InChI: InChI=1S/C20H28O5S/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25)/t17-,19-,20-/m1/s1
• InChIKey: IWCWQNVIUXZOMJ-MISYRCLQSA-N
• SMILES: CC(C)C1=C(C=C2C(=C1)CCC3C2(CCCC3(C)C(=O)O)C)S(=O)(=O)O

Ecabet (Cat No.:M014407) is a pharmaceutical compound known as a mucosal protective agent. Its chemical name is 4-[(2-Hydroxy-1-naphthalenyl)carbonyl]aminobenzoic acid. Ecabet is primarily used for its gastroprotective properties, enhancing the secretion of protective mucus in the gastrointestinal tract to prevent and treat conditions like gastric ulcers and gastritis. It also exhibits antioxidant and anti-inflammatory effects, making it potentially useful for inflammatory bowel disease.

Reference

1: Liang J, Li J, Han Y, Xia J, Yang Y, Li W, Zhang S, Wu Y, Yuan Y, Li Z, Du Y,
Chen M, Chen B, Jiang B, Bai Y, Wen Q, Wu K, Fan D. Helicobacter pylori
eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin
versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a
randomized, open-label, phase IV trial. Helicobacter. 2012 Dec;17(6):458-65. doi:
10.1111/j.1523-5378.2012.00971.x. Epub 2012 Jul 2. PubMed PMID: 23066868.

2: Wang Y, Wang B, Lv ZF, Yang Y, Wang F, Wang H, Chen S, Xie Y, Zhou X. Efficacy
and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori
eradication: a systematic review and meta-analysis. Helicobacter. 2014
Oct;19(5):372-81. doi: 10.1111/hel.12136. Epub 2014 May 14. Review. PubMed PMID:
24826809.

3: Furuta T, Kato M, Sugimoto M, Sasaki M, Kamoshida T, Furukawa K, Inaba T,
Tomita T, Shirai T, Ishii N, Nomura H, Konda Y, Asaka M; Japan Gast Study Group.
Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as
the rescue regimen for H. pylori infection. Intern Med. 2011;50(5):369-74. Epub
2011 Mar 1. PubMed PMID: 21372444.

4: Okuda M, Yamamoto N, Fukuda N, Maekawa K, Kusaka T, Hashimoto M, Kotake J,
Koizuka H, Fukuda Y. Effect of ecabet sodium treatment on urea breath test and
stool antigen tests in volunteers with Helicobacter pylori infection. J
Gastroenterol Hepatol. 2012 Apr;27 Suppl 3:100-2. doi:
10.1111/j.1440-1746.2012.07080.x. PubMed PMID: 22486880.

5: Wang Y, Tang N, Meng L, Zhang P, Xu K, Jiang N, Zhang H, Ou N, Wu D, Chen A,
Zhang X, Shi R. Safety and tolerability of bismuthyl ecabet suspension, a novel
anti-ulcer agent, following single and multiple oral dose administration in
healthy Chinese subjects. Clin Drug Investig. 2012 Apr 1;32(4):247-52. doi:
10.2165/11599110-000000000-00000. PubMed PMID: 22299715.